SGLT2 Inhibitors in Extra-Glycaemic Indications: Use in People with Renal Impairment

WooCommerce is required for FooEvents. Please install and activate the latest version of WooCommerce.

SGLT2 Inhibitors in Extra-Glycaemic Indications: Use in People with Renal Impairment - GPnotebook Education

This site is intended for healthcare professionals

This GPnotebook Shortcut provides dose recommendations for sodium–glucose co-transporter 2 (SGLT2) inhibitors according to renal impairment, specifically focusing on the use of these agents in indications other than the treatment of hyperglycaemia in type 2 diabetes.

The information provided herein should not be used for diagnosis or treatment of any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions. Any distribution or duplication of the information contained herein is strictly prohibited. GPnotebook Education stores small data files on your computer called cookies so that we can recognise you and provide you with the best service. If you do not want to receive cookies please do not use GPnotebook Education.